![Sindre Hassfjell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 356 409 $ in data 30/06/2026
Sindre Hassfjell is currently the Chief Technology Officer at Thor Medical ASA. Previously, he worked as the Director-Generator Development at Artbio AS.
He completed his undergraduate and graduate degrees at the University of Oslo in 1996 and 1997, respectively.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
THOR MEDICAL ASA 0,23% | 02/03/2026 | 825.001 ( 0,23% ) | 356 409 $ | 30/06/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| THOR MEDICAL | Direttore Tecnico/Scientifico/R&S | 01/06/2023 |
| Società | Posizione | Fine |
|---|---|---|
Artbio AS
 Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 3 |
|---|---|
University of Oslo
 University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artbio AS
Artbio AS BiotechnologyHealth Technology Operates as a clinical-stage radiopharmaceutical biotechnology business that works to create a new class of alpha radio ligand medicines | Health Technology |
Thor Medical ASA
 Thor Medical ASA Miscellaneous Commercial ServicesCommercial Services Produces and supplies alpha particle emitters for cancer therapy | Commercial Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
